Skip to main content
SpringerLink
Log in

90Y Ibritumomab Tiuxetan: profile report

  • New Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carswell CI, Wiseman LR. 90Y Ibritumomab Tiuxetan. Am J Cancer 2002; 1(5) 341–49

    Article  CAS  Google Scholar 

  2. Wun T. 90Y Ibritumomab Tiuxetan: a viewpoint. Am J Cancer 2002; 1(5) 349

    Article  Google Scholar 

  3. Niitsu N. 90Y Ibritumomab Tiuxetan: a viewpoint. Am J Cancer 2002; 1(5) 349

    Article  Google Scholar 

  4. Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999 Jul; 58: 79–88

    Article  PubMed  CAS  Google Scholar 

  5. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin’s lymphoma. Curr Pharm Biotechnol 2001 Dec; 2(4): 341–9

    Article  PubMed  CAS  Google Scholar 

  6. Alcindor T, Witzig TE. Radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin’s lymphoma. Curr Treat Options Oncol 2002 Aug; 3(4): 275–82

    Article  PubMed  Google Scholar 

  7. DeNardo GL, O’Donnell RT, Oldham RK, et al. A revolution in the treatment of non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 1998; 13(4): 213–23

    Article  PubMed  CAS  Google Scholar 

  8. IDEC Pharmaceuticals Corporation. Zevalin: product information. San Diego (CA): IDEC Pharmaceuticals Corporation, 2002 Jan

    Google Scholar 

  9. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2002 May 15; 20(10): 2453–63

    Article  PubMed  CAS  Google Scholar 

  10. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002 Aug 1; 20(15): 3262–9

    Article  PubMed  CAS  Google Scholar 

  11. IDEC Pharmaceuticals. Product: Zevalin [online]. Available from URL: http://www.idecpharm.com/site/science/zevalin.htm [Accessed 2002 May 13]

  12. Witzig TE, White CA, Gordon LI, et al. Zevalin radioimmunotherapy can be safely administered to patients with relapsed or refractory, B cell non-Hodgkin’s lymphoma [abstract]. Blood 2001 Nov 16; 98(Pt 1): 606

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

90Y Ibritumomab Tiuxetan: profile report. Drugs Ther. Perspect 18, 4–6 (2002). https://doi.org/10.2165/00042310-200218120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218120-00002

Keywords

Search

Navigation